ATRA — Atara Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $86.22m
- $117.89m
- $120.77m
Brief: Atara Biotherapeutics And Pierre Fabre Laboratories Announce Publication Of Phase 3 Allele Tab-Cel® Data In The Lancet Oncology
Brief: Atara Biotherapeutics To Close Global Tab-Cel® Partnership With Pierre Fabre Laboratories
Brief: Atara Biotherapeutics Presents Positive Preclinical Data On ATA3431
Brief: Ecor1 Capital, LLC Reports 9.9% Passive Stake In Atara Biotherapeutics As Of Nov 16
U.S. RESEARCH ROUNDUP-Axon Enterprise, Duolingo, Hubspot
Brief: Atara Biotherapeutics Announces Primary Analysis Data From Phase 2 EMBOLD Clinical Trial Of ATA188 In Non-Active Progressive Multiple Sclerosis
Brief: Atara Biotherapeutics Announces Expanded Global Tab-Cel Partnership With Pierre Fabre Laboratories
Brief: Atara Biotherapeutics Announces Plans To Submit Tab-Cel® BLA In Q2 2024 Following FDA Agreement On Comparability
Atara Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
Atara Biotherapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Atara Biotherapeutics Board Reduces Number Of Directors On Board
Brief: Atara Biotherapeutics Inc - On May 12, Jakob Dupont Resigned From The Company As Executive Vice President, Global Head Of Research And Development
Brief: Atara Biotherapeutics Announces First Quarter 2023 Financial Results
Atara Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
Atara Biotherapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Atara Biotherapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Atara Biotherapeutics Inc - Currently Maintains Account At Svb Holding Cash Deposits Of About $2 Million
Brief: Atara Biotherapeutics CFO To Step Down
Atara Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary